Navigation Links
Vasogen Announces Second Quarter 2009 Results
Date:7/14/2009

ed May 31, 2009 has decreased when compared with the same periods in 2008 due to the significant expenditures that were incurred during the 2008 periods to implement the restructuring that was announced on April 14, 2008. A portion of this decrease also relates to a $1.2 million non-cash provision taken against our clinical supplies during the three and six months ended May 31, 2008. This decrease is also the result of a significant reduction in the number of employees and a decision not to incur material expenditures to advance our products during the Company's ongoing strategic review process.

    Corporate Update

    -   To further reduce the rate at which we use our cash during our
        strategic review process, the employment of Graham Neil, our Vice-
        President, Finance, and CFO, was terminated effective July 14, 2009.
        Mr. Neil has agreed to fulfill the role of CFO, in a consulting
        capacity at substantially reduced compensation, to assist the Board
        in bringing closure to the ongoing strategic review process. As a
        result of this termination the number of full-time employees has been
        reduced to one.

    -   On April 24, 2009, we announced that Dr. Eldon R. Smith would succeed
        Terrance H. Gregg as Chairman of our Board of Directors due to the
        retirement of Mr. Gregg. Mr. Gregg's resignation from our Board is
        due to the requirements of his role as President and CEO of DexCom,
        Inc. In connection with his appointment, Dr. Smith's position as our
        Senior Vice President, Scientific Affairs and Chief Medical Officer
        was terminated.

    -   Pursuant to our restructuring plan, our Board of Directors and
        Management had been actively involved in a process of screening,
        reviewing, and short-listing potential opportunities, including the
        sale of the Company or a merger or acquisition, and exploring the
       
'/>"/>
SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014  Having the right people ... vital to accelerating business growth and achieving clinical and ... Association (AHA) Leadership Summit, July 20-22, 2014, in ... of hospital executives and healthcare experts discussing how partnerships ... Carrocino , President & Chief Executive Officer of Cape ...
(Date:7/23/2014)... StemGenex® , the leading resource for ... at improving the lives of patients dealing with degenerative ... disease. StemGenex believes that a commitment to the ... when providing care to patients with degenerative diseases. ... accessible to the millions of individuals currently living with ...
(Date:7/23/2014)... Iowa (PRWEB) July 23, 2014 DuPont ... the business as vice president of Agricultural Biotechnology (ABT), ... Biotechnology where he served most recently as president, chief ... biotechnology and business leadership in the seed and crop ... said Paul E. Schickler , president of DuPont ...
(Date:7/23/2014)... -- regulated information -- UCB today announced an important ... positive topline results from the latest Phase 3 ... to evaluate the efficacy and safety of ... compared to placebo, as adjunctive treatment in adult ... controlled despite treatment with one or two concomitant ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... that the anticoagulant Clexane(R) (enoxaparin sodium injection) ... the Ministry of Health, Labour and,Welfare for ... patients,undergoing orthopaedic surgery of the lower limbs ... and hip fracture surgery., Venous thromboembolism ...
... 25 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Healthcare Conference on Wednesday, January 30, at 8:30,a.m. ... webcast of the,presentation at:, http://www.wsw.com/webcast/wa48/onxx/ , ... 15 minutes early in order to,register and download ...
... 0641-2440-45, 0641-2440-41, 0641-2450-45 and 0641-2450-41;, LOTS: 107054, 117085, 047056, 097081, ... ... 107111, DEERFIELD, Ill., Jan. 25 Baxter Healthcare,Corporation has announced the ... 30mL multi-dose vials. The company,began recalling the lots on January 17, 2008 ...
Cached Biology Technology:Clexane(R)/Lovenox(R) Approved in Japan 2Clexane(R)/Lovenox(R) Approved in Japan 3Clexane(R)/Lovenox(R) Approved in Japan 4Clexane(R)/Lovenox(R) Approved in Japan 5Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials 2
(Date:7/23/2014)... BOSTON , July 23, 2014 ... and threat detection, announced today it has been named ... . The Market Guide replaces Gartner,s well-known Magic Quadrant ... Gartner categorized BioCatch as one of several vendors to ... biometric analysis will become a standard feature of at ...
(Date:7/23/2014)... temperature around the world by 2050, according to one ... Climate Change (IPCC), may be advantageous to the physiology ... growth of forage plants such as Stylosanthes capitata ... tropical countries such as Brazil., The conclusion is from ... of Biology at the Ribeiro Preto Faculty of Philosophy, ...
(Date:7/23/2014)... sulfur-oxidizing bacterial group called SUP05 will play an increasingly ... world,s oceans as oxygen minimum zones expand, according to ... the National Academy of Sciences . , University of ... anoxic fjord, Canada,s Saanich Inlet, to chart how microbial ... "Our study paints a very detailed picture of how ...
Breaking Biology News(10 mins):BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... Vein Authentication Technology with, Single-Sign On Solutions Cost-Effectively Bolsters ... ... SUNNYVALE, Calif., Sept. 9 Fujitsu Computer Products of,America, ... disk drives, peripherals and biometric security solutions, today,announced the ...
... Nearly 40 percent of fish species in North American ... to the most detailed evaluation of the conservation status ... The 700 fishes now listed represent a staggering ... in the previous 1989 study published by the American ...
... RUNX3 gatekeeper gene paves the way for the growth and ... issue of the journal Cancer Cell . Previous ... breast, lung and bladder cancers. The inactivation of RUNX3 ... to the Singapore scientists, studies with human tissue samples and ...
Cached Biology News:Fujitsu Announces PalmSecure(TM) LOGONDIRECTOR 2Fujitsu Announces PalmSecure(TM) LOGONDIRECTOR 3Fujitsu Announces PalmSecure(TM) LOGONDIRECTOR 4Silent streams? Escalating endangerment for North American freshwater fish 2Silent streams? Escalating endangerment for North American freshwater fish 3Early stage colon cancer characterized by inactivation of gatekeeper gene 2
... enterprise microarray informatics platform for microarray data storage, ... and use it forever without paying ongoing license ... Acuity has all the analysis tools you need ... quality control statistics and normalization, all the way ...
... industry standard microarray image analysis software because ... analysis tools, visualizations, automation capabilities, performance and ... with every GenePix scanner, and it also ... all types of arrays. A wide range ...
A univariate (peak height or area) quantitative multi-component analysis package....
... H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 (Disulfide ... peptide and 1 ... I-labelled peptide, please see ... ([ 1 2 ...
Biology Products: